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Rhythm Control
for Atrial Fibrillation
Favorable Outcomes or Futile Endeavor?*
Steven M. Markowitz, MD
New York, New York
Numerous studies have established that atrial fibrillation
(AF) is an important cause of stroke, an exacerbating factor
for heart failure, a common reason for hospital stay, and an
independent predictor of mortality (1,2). Therefore, it
seems logical that suppression of AF would improve out-
comes, particularly in those at highest risk of complications.
This hypothesis has been tested in several clinical trials,
targeting different populations with AF and measuring
various outcomes ranging from survival to quality of life
(3–8). The largest and most influential of these trials was
the AFFIRM (Atrial Fibrillation Investigation of Rhythm
Management) trial, which compared strategies of rhythm-
control—consisting of cardioversion and antiarrhythmic
drug (AAD) therapy—with rate control with conventional
atrioventricular nodal blocking agents (5). The AFFIRM
trial enrolled over 4,000 patients with AF at high risk for
death or stroke and examined the primary endpoint of
overall survival. The design of the study was intended to
mimic clinical practice and permitted enrolling physicians to
choose among the range of available AADs on the basis of
patient characteristics.
See page 1975
Counterintuitively, the AFFIRM trial showed no advan-
tage to the rhythm-control strategy and in fact demon-
strated a trend to higher mortality in rhythm-control
patients. The inability to demonstrate benefit for rhythm
control has been replicated in other cohorts, such as those
with heart failure (8). If AF is an independent predictor of
mortality and is causally associated with stroke, why has it
not been possible to show improved outcomes for rhythm-
control in clinical trials? A number of explanations have
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explanation is that AADs are relatively ineffective (5,9). For
example, in the AFFIRM trial the prevalence of sinus
rhythm in the rhythm-control group was only 63% at 5
years, despite the use of serial AADs. A second explanation
for the unexpected finding is that AADs possess toxicities
that might abolish the advantages of maintaining sinus
rhythm (10).
Individual AADs differ in their efficacies, toxicities, and
potential impact on survival. Amiodarone is generally re-
garded as the most potent AAD in suppressing AF recur-
rences, as reflected by the observation that almost two-
thirds of patients randomized to rhythm-control in the
AFFIRM trial eventually received amiodarone. Yet, the
risks of noncardiac toxicity with amiodarone are widely
appreciated. Cardiac toxicity in the form of proarrhythmia is
a concern with every AAD, although the types and risks of
proarrhythmia vary among the available agents. An early
signal of danger with AAD therapy for AF came from a
retrospective analysis of the SPAF (Stroke Prevention in
Atrial Fibrillation) study, which showed increased risk of
death among patients with heart failure who received
AADs, primarily Class 1A and 1C agents (11). Similarly, a
meta-analysis of 6 randomized trials showed excess mortal-
ity in AF patients randomized to quinidine (12). Clearly,
therapies for AF must be evaluated for clinical outcomes
beyond the maintenance of sinus rhythm.
In this issue of the Journal, Saksena et al. (13) analyzed
the AFFIRM database to assess the impact of individual
AADs on mortality and hospital stays. To account for bias
in drug assignments, which were not randomized in the
main AFFIRM study, the investigators developed a propen-
sity score that included 64 clinical variables that they used to
match AAD patients with control subjects. They identified
1,603 AAD-treated patients with matched control subjects
and analyzed cohorts of patients whose first AADs in the
trial were amiodarone (45%), sotalol (38%), or the Cass 1C
drugs flecainide or propafenone (17%). The primary out-
come measure was the composite of mortality or first
cardiovascular hospital stay (CVH). The rationale for this
endpoint is that CVH are costly and predict overall mor-
tality (14). Because CVH occur more frequently than death,
this endpoint has a higher power to detect moderate
differences in outcomes, permitting the design of smaller
clinical trials.
The analysis showed that rhythm-control patients had
higher risk of death or first CVH. With regard to individual
AADs, the amiodarone and sotalol groups fared worse than
their matched control subjects, and there was a trend to
worse outcomes in the Class 1C patients (the latter due
perhaps to a smaller sample size that was underpowered to
demonstrate statistical significance). Not surprisingly, spe-
cific subgroups were at higher risk of CVH, notably patients
with baseline coronary disease and heart failure, those with
worsening angina or heart failure symptoms during the trial,
1987JACC Vol. 58, No. 19, 2011 Markowitz
November 1, 2011:1986–8 Antiarrhythmic Drugs and Hospital Stayand those with AF recurrences. Nevertheless, AAD treat-
ment remained an independent predictor of CVH when
adjusted for these covariates. There were no significant
differences in overall survival between AAD groups and
their matched control subjects, but the amiodarone group
trended toward a higher mortality. Of interest, amiodarone-
treated patients were at increased risk of noncardiovascular
death and a composite endpoint of death and intensive care
unit hospital stay.
This study does not clarify why AAD therapy was
associated with a higher risk of CVH, because specific
causes of hospital stay were not reported in the AFFIRM
trial. The higher rate of CVH in the rhythm-control
subgroups could not be explained by hospital admissions to
change AADs or perform cardioversions, which comprised
a small percentage of the hospital stays. Most hospital stays
were long (3 days), and many involved intensive care unit
stays, suggesting severe illnesses. One might speculate that
AAD-treated patients were hospitalized more often because
of worsening heart failure. Certainly, sotalol and Class 1C
drugs could exacerbate heart failure, but amiodarone has
been safely used in heart failure cohorts (15). An excess of
strokes could account for more hospital stays among
rhythm-control patients, who were more likely to discon-
tinue anticoagulation. However, this seems to be an unlikely
explanation, because the annual rate of stroke in the
AFFIRM trial was relatively low (approximately 1%) in
both the rhythm- and rate-control arms (16). In the present
analysis, strokes, emboli, and bleeding together accounted
for only a minority of CVH. Proarrhythmia also does not
explain the findings of this study, because this phenomenon
was observed at a low rate in the AFFIRM trial (17).
Furthermore, it is difficult to implicate myocardial ischemia,
because amiodarone and sotalol exert beta-blocker activity
and have anti-ischemic effects. It is plausible that some of
these hospital stays were related to bradyarrhythmias and
requirement for permanent pacemakers, but this does not
explain the totality of the findings. Further study is needed
to determine why these AADs would precipitate serious
hospital stays.
It is difficult to conclude from this analysis that one AAD
is necessarily “safer” than another. Although there was a
trend for increased mortality with amiodarone compared
with rate control, this association did not reach statistical
significance and should be regarded as hypothesis-generating. In
the heart failure and post-infarction populations, amiodarone
demonstrates no excess mortality (15,18,19). These contrary
findings might be explained by the fact that heart failure and
post-infarction trials targeted different patients than the
AFFIRM trial. In “less ill” AF patients, the risks of
amiodarone toxicity could potentially outweigh the benefits.
It is also worth noting that efforts were made in the
AFFIRM trial to minimize complications from AADs by
urging caution in the use of Class 1C drugs for those with
structural heart disease and in the use of sotalol for those
with heart failure. Despite these advisories, this reportshows that many patients who received Class 1C drugs were
coded as having coronary disease and/or heart failure, and
many who received sotalol were also classified as having
heart failure. Conceivably, these patients might have suf-
fered complications such as proarrhythmia or heart failure
exacerbations. Although patients with coronary disease or
heart failure were hospitalized more often, the study did not
show an interaction between these conditions and AAD
assignments with regard to CVH. Plainly, the selection of
safe AAD therapy on the basis of patient clinical profile is
still complex and challenging.
Regardless of these cautionary findings, it is premature to
regard rhythm-control as a futile endeavor. As has been
acknowledged elsewhere, the results from rate- versus
rhythm-control trials cannot necessarily be applied to
younger patients, those with fewer comorbidities, or those
who poorly tolerate AF despite rate-control attempts (5).
Even among those at higher risk, sinus rhythm might be
preferable. A subanalysis of the AFFIRM trial indicated
that maintenance of sinus rhythm was independently asso-
ciated with better survival, potentially counter-balanced by
the worsened survival associated with AAD exposure (10).
In a randomized trial of dofetilide, maintenance of sinus
rhythm was also associated with better survival (20). In
contrast to the AFFIRM findings, dronedarone has been
shown to reduce CVH among older patients with nonper-
manent AF who have risk factors for stroke (21). These
findings should spur the search for less toxic and more
effective antiarrhythmic therapies. It is unknown at this time
whether nonpharmacological treatments such as catheter
ablation will prevent hospital stays and improve survival in
AF patients. To date, only nonrandomized observational
studies have evaluated survival after ablation and show that
survival is better among AF patients who underwent abla-
tion compared with those managed medically (22). These
intriguing findings indicate that the rate- versus rhythm-
control debate is far from over. The present study adds to
this debate by emphasizing the need to evaluate new
therapies not only in terms of antiarrhythmic efficacy but
also with regard to mortality and hospital stays.
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